Zacks Research Brokers Increase Earnings Estimates for BHC

Bausch Health Companies Inc. (NYSE:BHC) – Investment analysts at Zacks Research raised their Q1 2025 earnings estimates for Bausch Health Companies in a research note issued on Monday, January 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.87 per share for the quarter, up from their previous estimate of $0.85. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $1.04 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.15 EPS and Q3 2026 earnings at $1.38 EPS.

Several other research firms have also recently weighed in on BHC. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Royal Bank of Canada increased their target price on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research note on Friday, November 1st. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Bausch Health Companies has a consensus rating of “Hold” and an average target price of $7.75.

Bausch Health Companies Trading Up 0.4 %

BHC stock opened at $7.47 on Wednesday. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The firm’s 50-day moving average price is $7.88 and its two-hundred day moving average price is $7.45. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of -15.56 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the business earned $1.03 EPS. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BHC. Mackenzie Financial Corp grew its stake in Bausch Health Companies by 111.0% in the second quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after purchasing an additional 1,252,834 shares during the last quarter. LMR Partners LLP purchased a new position in shares of Bausch Health Companies during the third quarter worth $3,264,000. Clearline Capital LP purchased a new stake in shares of Bausch Health Companies in the second quarter worth about $6,881,000. Intact Investment Management Inc. purchased a new position in shares of Bausch Health Companies during the 3rd quarter valued at approximately $1,543,000. Finally, XTX Topco Ltd purchased a new stake in shares of Bausch Health Companies during the 3rd quarter worth about $938,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.